UCB, Inc. drugs

9 results

  • bimzelx

    (bimekizumab)
    UCB, Inc.
    BIMZELX is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who qualify for systemic therapy or phototherapy.

  • briviact

    (brivaracetam)
    UCB, Inc.
    BRIVIACT is indicated for the treatment of partial-onset seizures in patients aged 1 month and older.

  • cimzia

    (certolizumab pegol)
    UCB, Inc.
    CIMZIA is indicated for treating moderate to severe Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults and eligible pediatric patients aged 2 years and older.

  • fintepla

    (fenfluramine)
    UCB, Inc.
    FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome in patients aged 2 years and older.

  • nayzilam

    (midazolam)
    UCB, Inc.
    NAYZILAM is indicated for the acute treatment of intermittent, stereotypic seizure clusters or acute repetitive seizures in epilepsy patients aged 12 years and older, which are distinct from their usual seizure patterns.

  • neupro

    (rotigotine)
    UCB, Inc.
    NEUPRO is indicated for the treatment of Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome (RLS).

  • rystiggo

    (ROZANOLIXIZUMAB)
    UCB, Inc.
    RYSTIGGO is indicated for treating generalized myasthenia gravis (gMG) in adult patients who test positive for either anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies.

  • univasc

    (moexipril hydrochloride)
    UCB, Inc.
    Univasc® is indicated for treating hypertension, either alone or with thiazide diuretics. Caution is advised due to potential risks of agranulocytosis and variations in efficacy and angioedema rates between black and non-black patients.

  • vimpat

    (lacosamide)
    UCB, Inc.
    VIMPAT is indicated for the treatment of partial-onset seizures in patients aged 1 month and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older.